OSE Immunotherapeutics Salute del bilancio

Salute finanziaria criteri di controllo 5/6

OSE Immunotherapeutics ha un patrimonio netto totale di €81.4M e un debito totale di €40.4M, che porta il suo rapporto debito/patrimonio netto a 49.6%. Le sue attività totali e le sue passività totali sono rispettivamente €140.9M e €59.5M. L'EBIT di OSE Immunotherapeutics è €53.8M rendendo il suo rapporto di copertura degli interessi 23.2. Ha liquidità e investimenti a breve termine pari a €75.7M.

Informazioni chiave

49.6%

Rapporto debito/patrimonio netto

€40.39m

Debito

Indice di copertura degli interessi	23.2x
Contanti	€75.75m
Patrimonio netto	€81.45m
Totale passività	€59.47m
Totale attività	€140.92m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%

Oct 19

Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings

Oct 04

Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?

May 23

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Oct 02

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Apr 30

OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

May 11

Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?

May 08

Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher

Mar 16

How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?

Dec 01

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €85.8M ) di OSE superano le sue passività a breve termine ( €17.4M ).

Passività a lungo termine: Le attività a breve termine di OSE ( €85.8M ) superano le sue passività a lungo termine ( €42.1M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: OSE ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di OSE è aumentato da 8.2% a 49.6% negli ultimi 5 anni.

Copertura del debito: Il debito di OSE è ben coperto dal flusso di cassa operativo ( 144.5% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di OSE sono ben coperti dall'EBIT ( 23.2 x copertura).

OSE Immunotherapeutics Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?

Recent updates

Investor sentiment improves as stock rises 17%

OSE Immunotherapeutics SA (EPA:OSE) Held Back By Insufficient Growth Even After Shares Climb 31%

Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings

First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

Price target increased by 42% to €10.15

New major risk - Revenue and earnings growth

OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco

Forecast breakeven date moved forward to 2024

Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

Consensus revenue estimates increase by 59%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2025

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

New minor risk - Shareholder dilution

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

Consensus revenue estimates fall by 73%

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

First half 2023 earnings released: €0.64 loss per share (vs €0.11 loss in 1H 2022)

New major risk - Financial position

Forecast breakeven date moved forward to 2024

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

Price target decreased by 14% to €10.80

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

High number of new directors

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

Price target decreased by 7.7% to €12.00

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

Forecast to breakeven in 2025

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

Consensus forecasts updated

Price target decreased to €15.03

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

Consensus forecasts updated

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-Il-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis After the Interim Futility Analysis

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, Its Multi-Target T-Cell Anti-COVID Vaccine

First half 2021 earnings released: €0.64 loss per share (vs €0.21 loss in 1H 2020)

OSE Immunotherapeutics SA to Present Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Esmo 2021

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi in Combination with Pembrolizumab in Ovarian Cancer

Servier and OSE Immunotherapeutics SA Announces Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

OSE Immunotherapeutics SA Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

Ose Immunotherapeutics and the Fort Foundation Announce Initiation of A Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer